Skip to main content

ERRATUM article

Front. Pharmacol., 07 March 2023
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1173490

Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

This article is an erratum on:

  1. Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

by Boudou C, Mattio L, Koval A, Soulard V and Katanaev VL (2022). Front. Pharmacol. 13:1045102. doi: 10.3389/fphar.2022.1045102

An omission to the Funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Geneva.”

The original version of this article has been updated.

Keywords: Wnt signaling, triple-negative breast cancer, β-catenin, cancer survival, medicinal chemistry, structure activity relationship, thienopyrimidine, quinazoline

Citation: Frontiers Production Office (2023) Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors. Front. Pharmacol. 14:1173490. doi: 10.3389/fphar.2023.1173490

Received: 24 February 2023; Accepted: 24 February 2023;
Published: 07 March 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.